We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
+2.58%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.09B
AUM Growth
-$12.9M
Cap. Flow
+$54.2M
Cap. Flow %
4.96%
Top 10 Hldgs %
67.6%
Holding
30
New
7
Increased
10
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$72M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$51.4M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$45M
4
PCRX icon
Pacira BioSciences
PCRX
+$36.8M
5
DVAX
Dynavax Technologies
DVAX
+$28.6M

Top Sells

Rank Stock Value
1
MDXG icon
MiMedx Group
MDXG
+$75.5M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$66.9M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$50.6M
4
ARGX icon
argenx
ARGX
+$49.5M
5
AMRN
Amarin Corp
AMRN
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 89.58%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FLXN
26
DELISTED
Flexion Therapeutics, Inc.
FLXN
$4.65M 0.42%
+207,392
New +$5.06M
ARGX icon
27
argenx
ARGX
$52.8B
– –
-783,869
Closed -$49.5M
MDXG icon
28
MiMedx Group
MDXG
$622M
– –
-5,990,682
Closed -$75.5M
SPNE
29
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
– –
-21,428
Closed -$217K
LJPC
30
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-2,079,311
Closed -$66.9M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q1 2018 Portfolio in Review

As of Q1 2018, Consonance Capital Management held 30 positions worth $1.09B, down 1.2% from $1.11B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Consonance Capital Management deployed $54.2M of net new capital in Q1 2018, opening 7 new positions and adding to 10 existing holdings. Its largest new stake was United Therapeutics: 566,926 shares worth $63.7M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $50.6M trimmed.

  • Consonance Capital Management's largest Q1 2018 buy was United Therapeutics: 566,926 shares worth $63.7M.
  • Consonance Capital Management added most to Iovance Biotherapeutics in Q1 2018, an estimated $45M increase.
  • Consonance Capital Management's biggest Q1 2018 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $50.6M.
  • Consonance Capital Management fully exited MiMedx Group in Q1 2018, selling an estimated $75.5M.
  • Consonance Capital Management's ten largest holdings make up 68% of its $1.09B portfolio in Q1 2018.
  • Consonance Capital Management opened 7 new positions and closed 4 in Q1 2018.
  • Consonance Capital Management's portfolio value fell 1.2% quarter-over-quarter to $1.09B.

Based on Consonance Capital Management's 13F filing for Q1 2018, filed 15 May 2018.